Latest news
StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Mon, 03 Aug 2026 00:49:26 GMTMapLight Therapeutics stock crashes on Phase II schizophrenia data - Clinical Trials ArenaClinical Trials Arena · Tue, 28 Jul 2026 14:17:49 GMTMapLight's schizophrenia candidate clears one bar but misses another - The Pharma LetterThe Pharma Letter · Tue, 28 Jul 2026 07:00:00 GMTMPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose - TradingViewTradingView · Mon, 27 Jul 2026 23:08:32 GMTMapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia - The Manila TimesThe Manila Times · Mon, 27 Jul 2026 11:17:27 GMTPhase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia - Psychiatric TimesPsychiatric Times · Mon, 27 Jul 2026 07:00:00 GMTMapLight shares sink on mixed ph. 2 schizophrenia readout - Fierce BiotechFierce Biotech · Mon, 27 Jul 2026 07:00:00 GMTMPLT: Phase 2 ZEPHYR met its primary endpoint, showing robust efficacy and cognitive benefit in schizophrenia - TradingViewTradingView · Mon, 27 Jul 2026 07:00:00 GMT